Dynavax Technologies (DVAX) Rating Increased to Sell at BidaskClub

BidaskClub upgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a strong sell rating to a sell rating in a report published on Tuesday, May 7th, BidAskClub reports.

Several other research firms have also recently weighed in on DVAX. ValuEngine cut Dynavax Technologies from a hold rating to a sell rating in a research report on Monday, February 4th. Cantor Fitzgerald reaffirmed an overweight rating and set a $28.00 price objective (down from $32.00) on shares of Dynavax Technologies in a research report on Tuesday, February 26th. Finally, Zacks Investment Research cut Dynavax Technologies from a hold rating to a sell rating in a research report on Monday, March 4th. Three equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $23.67.

Shares of DVAX stock traded down $0.15 on Tuesday, reaching $4.82. 981,051 shares of the stock were exchanged, compared to its average volume of 1,121,538. The company has a market cap of $313.61 million, a P/E ratio of -1.89 and a beta of 0.60. The company has a quick ratio of 4.61, a current ratio of 5.27 and a debt-to-equity ratio of 4.88. Dynavax Technologies has a one year low of $4.69 and a one year high of $17.05.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. Dynavax Technologies had a negative return on equity of 190.84% and a negative net margin of 1,156.11%. The firm had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $5.95 million. During the same period in the previous year, the firm earned ($0.63) earnings per share. The company’s revenue was up 3294.1% on a year-over-year basis. As a group, equities research analysts anticipate that Dynavax Technologies will post -2.18 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Falcon Point Capital LLC increased its stake in shares of Dynavax Technologies by 54.5% during the fourth quarter. Falcon Point Capital LLC now owns 30,944 shares of the biopharmaceutical company’s stock worth $283,000 after purchasing an additional 10,921 shares during the period. Chicago Capital LLC increased its stake in shares of Dynavax Technologies by 18.8% during the first quarter. Chicago Capital LLC now owns 2,544,142 shares of the biopharmaceutical company’s stock worth $18,598,000 after purchasing an additional 402,411 shares during the period. Vanguard Group Inc. increased its stake in shares of Dynavax Technologies by 1.0% during the third quarter. Vanguard Group Inc. now owns 2,883,887 shares of the biopharmaceutical company’s stock worth $35,759,000 after purchasing an additional 29,898 shares during the period. Clearbridge Investments LLC increased its stake in shares of Dynavax Technologies by 1,189,548.7% during the third quarter. Clearbridge Investments LLC now owns 904,133 shares of the biopharmaceutical company’s stock worth $11,211,000 after purchasing an additional 904,057 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Dynavax Technologies during the third quarter worth approximately $974,000. Hedge funds and other institutional investors own 81.97% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Featured Story: Hedge Funds – How They Work For Investors

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.